Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT LONDON and RALEIGH, N.C., Oct.
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved